CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
MEDI3250drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02269488
NCT02269488Phase 3Completed
CompareCT.gov

A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

AstraZeneca·interventional·Posted Oct 21, 2014·Updated Sep 28, 2015

In Brief

A Phase 3 clinical trial evaluating MEDI3250 for Healthy Japanese Children Age 2 Years Through 6 Years. Completed, enrolled 100 participants across 3 sites.

Detailed Summary

This open-label, single arm, multicenter study will enroll approximately 100 subjects. The study is designed to gather the safety and tolerability data in Japanese children 2 to 6 years of age that would support approval of MEDI3250 in Japan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Japanese Children Age 2 Years Through 6 Years
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 21, 2014
Enrollment StartNov 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.7 years ago

Interventions

MEDI3250drug

MEDI3250